Clinical Trials Logo

Aggressive Systemic Mastocytosis clinical trials

View clinical trials related to Aggressive Systemic Mastocytosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04695431 Completed - Mast Cell Leukemia Clinical Trials

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Start date: December 2, 2020
Phase:
Study type: Observational

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

NCT ID: NCT02561988 Completed - Mast Cell Leukemia Clinical Trials

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Start date: March 10, 2016
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

NCT ID: NCT01807598 Completed - Mast Cell Leukemia Clinical Trials

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them